Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01919996 · ClinicalTrials.gov registry record · Phase 2

PASS Study To Evaluate The Potential Of Zithromax To Cause Ocular Problems In Pediatric Patients

A Phase 2 study, sponsored by Pfizer.

Terminated
Registry status
Phase 2
Development phase
8
Enrollment target

NCT01919996: Clinical Trial Phase 2 study, sponsored by Pfizer.

NCT01919996 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 8 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01919996, a Phase 2 study, was terminated before completion, sponsored by Pfizer.

TERMINATED
Registry status
Phase 2
Development phase
8 participants
Enrollment target

Study Summary

This Post-Authorization Safety Study (PASS) is intended to fulfill a regulatory post-marketing requirement to provide data regarding visual abilities in children taking azithromycin (immediate-release formulation) for acute pharyngitis/tonsillitis. The primary objective of the study is to examine the incidence of clinically significant worsening in any of the following ophthalmic exams: best corrected visual acuity (distance), color vision, Amsler grid testing, anterior segment biomicroscopy, and fundus examination, in a group of approximately 30 pediatric patients taking azithromycin oral solution for treatment of an authorized indication of use (pharyngitis/ tonsillitis).

Primary Outcome

Clinically significant worsening is an observed worsening in any of the five ophthalmic exams: 1) Clinically significant worsening in best corrected visual activity (BCVA) (distance) at the final visit, in either eye, is defined as a decrease in score of 5 or more letters from baseline in Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA. 2) An assessment of abnormal clinically significant at final visit in color vision Farnsworth Munsell 100 Hue Test (FM-100) in either eye. 3) An assessme

Interventions

  • DRUG Azithromycin

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2013-12
Est. Completion 2015-11
Phase Phase 2
Pfizer

1,845 total trials

Why NCT01919996 stopped before completion

NCT01919996 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower).

The record links to 0 conditions, and to 1 intervention - of which Azithromycin is the first listed.

NCT01919996 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01919996 about?

NCT01919996 is a clinical study titled "PASS Study To Evaluate The Potential Of Zithromax To Cause Ocular Problems In Pediatric Patients". This Post-Authorization Safety Study (PASS) is intended to fulfill a regulatory post-marketing requirement to provide data regarding visual abilities in children taking azithromycin (immediate-release formulation) for acute pharyngitis/tonsillitis. The primary objective of the study is to examine th...

What is the current status of trial NCT01919996?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2013-12. Estimated completion is 2015-11.

What interventions are being tested in trial NCT01919996?

The interventions under investigation include: Azithromycin (DRUG).

Who is sponsoring clinical trial NCT01919996?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01919996's enrollment target sits among peer trials

8 1990th of 2000 higher than 5 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01919996, the US trial registry maintained by the National Library of Medicine. NCT01919996 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.